Danielle Bucco

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.

Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.

Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.

Susan R. Rheingold, MD, discusses the impact of CAR T-cell therapy on patients with ALL and options for patients who relapse on treatment.

Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

Stephan Grupp, MD, PhD, discusses the phase II ELIANA study results and the next steps with chimeric antigen receptor T-cell therapy in acute lymphoblastic leukemia.

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.